Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to ease HIV stigma for expectant mothers in ghana

NCT ID NCT07064928

Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study adapts an existing stigma-reduction program specifically for pregnant and postpartum women living with HIV in Ghana. Researchers will interview 30 women and 20 providers to understand their experiences, then work with stakeholders to tailor the program. Finally, 90 pregnant women will test the adapted program to see if it reduces stigma and improves mental health and medication adherence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Adapted Project Accept's Post-Test Support Services (PTSS) Module 3 (behavioral intervention)
What this could lead to
If successful, this could lead to a tailored program that reduces HIV-related stigma and improves mental health and treatment adherence for pregnant and postpartum women in Ghana.
What could go wrong
This is an early adaptation and feasibility study with only 90 women in the pilot test, so results may not be generalizable. The intervention is behavioral, so its impact may be limited without broader societal changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 175 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Diagnosed with HIV * Between 24-36 weeks gestation at enrollment * Willing to participate during the postpartum period Recruitment process: * Approached during a prenatal visit by a nurse/midwife * Interested women will be connected with a trained research assistant (RA) * RA will explain the study to potential participants Exclusion criteria: * Critically ill and hospitalized pregnant WLWH * Pregnant WLWH not planning to live in the region for at least 6 months after childbirth * Pregnant WLWH under 13 years old, under parental supervision, and attending mandatory school Eligibility of healthcare providers: * All providers at the four sites invited to a session at their site * Providers eligible if they have worked with WLWH or pregnant/postpartum women for at least 2 months * Providers who do not consent to be interviewed will not be included

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression - major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS Depression depressive disorder HIV infectious disease major depressive disorder Psychological Well-Being puerperal disorder Social Stigma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression - major depressive disorder HIV HIV (human immunodeficiency virus) Mental health Mental health (depression) Postpartum Pregnancy Pyschological distress STIGMA Stigma, social

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ashaiman Polyclinic

    Accra, Ghana

More trials for these conditions

Other studies related to the condition(s) this trial covers.